Healthcare
Suven Life Sciences Reaches 76% Enrollment in Global Phase 3 Masupirdine Trial
Suven Life Sciences Limited reaches 76% enrollment in its Global Phase 3 Masupirdine trial for Alzheimer’s agitation.
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, announced a significant milestone in its Global Phase 3 Masupirdine (SUVN-502) trial. The company has reached a 76% enrollment in its 375-patient, multi-center, randomized, double-blind, placebo-controlled study for treating agitation in patients with dementia of the Alzheimer’s type (AAD).
Study Details
The study, conducted across North America and Europe, aims to evaluate the efficacy and safety of Masupirdine. The primary endpoint measures the change from baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) items. The trial is expected to complete enrollment by the end of 2026, with the last patient last visit anticipated in Q1, 2027.
Company Goals
Mr. Venkat Jasti, Chairman and Managing Director, emphasized the company’s commitment to advancing the study towards completion. He stated, “Our goal is to advance the study towards completion with definitive timelines.” The company aims to report results potentially in Q2/Q3, 2027.
Potential Impact
Dr. Ramakrishna Nirogi, President and CSO, highlighted the potential of Masupirdine as a differentiated, non-dopaminergic, non-sedative approach for managing Alzheimer’s agitation. He noted, “Masupirdine has the potential to offer a transformative approach, delivering dual impact on behavioral stabilization and cognition.”
As the study progresses, Suven Life Sciences Limited continues to leverage multiple resources and AI-enabled patient identification to accelerate enrollment and achieve study goals.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Suven Life Sciences Limited
Suven Life Sciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Suven rises 37.5% over three months, with buying pressure holding steady. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. Buyers show up with 1.9x the volume of sellers. Moreover, they dominated on 21 of recent sessions versus 9 for sellers — a healthy accumulation pattern. The stock rises 37.5% in three months. Yet revenue grows at only -17.5% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Suven Life Sciences Limited.
ALKEM
Alkem Laboratories Limited Q2fy27: Revenue Growth of 14%
Alkem Laboratories Limited (ALKEM) reports 14% revenue growth in Q2FY27, with strong performance in both domestic and international segments.
Alkem Laboratories Limited (NSE: ALKEM) announced its standalone and consolidated financial results for the second quarter ended September 30, 2026, reflecting a robust performance. The Board of Directors reviewed these results at its meeting held in Mumbai today. Commenting on the results, Mr. Sandeep Singh, Managing Director of Alkem, stated, “Our Q2FY27 performance reflects continued momentum in the India business, supported by focused execution across our acute and chronic portfolios. The international business delivered steady progress despite continued pricing pressure in the US, with volume growth providing support.”
Q2FY27 Key Financial Highlights
Total Revenue from Operations was ₹45,520 million, with a year-on-year growth of 13.8%. India sales were ₹30,275 million, showing a YoY growth of 9.5%. International sales were ₹14,540 million, with a YoY growth of 22.3%. EBITDA at ₹10,252 million resulted in an EBITDA margin of 22.5%, a growth of 11.3% YoY. Profit before tax (before exceptional item) was ₹9,646 million, with a YoY growth of 7.7%. Net Profit (after Non-Controlling interest) was ₹6,753 million, with a YoY de-growth of 11.7%.
Operational Highlights
The contribution of domestic sales to total sales was 68% vs. 70% in Q2 FY26. US sales were ₹7,830 million, with a YoY growth of 2.4%. Non-US sales were ₹6,710 million, with a YoY growth of 58%.
For more information, please visit www.alkemlabs.com and follow us on LinkedIn, Instagram, and Facebook.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Alkem Laboratories Limited
Alkem Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Alkem moves sideways over three months, with neither buyers nor sellers taking control. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The PEG of 0.92 signals undervaluation relative to growth. It is a potential re-rating candidate. The stock gains 4.7% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 8.3% and profits at 32.7%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alkem Laboratories Limited.
Healthcare
Suven Life Sciences Limited to Present Seven Scientific Posters at Neuroscience 2026
Suven Life Sciences Limited (SUVEN) to present seven scientific posters at Neuroscience 2026, showcasing CNS drug discovery.
Suven Life Sciences Limited (SUVEN) announced its participation in Neuroscience 2026, the annual meeting of the Society for Neuroscience (SfN), to be held in Washington, DC, USA, from November 14-18, 2026. The company will present seven scientific posters highlighting its drug discovery and development programs targeting central nervous system (CNS) disorders.
Diverse Portfolio of Drug Candidates
The presentations span a diverse range of therapeutic areas, including Alzheimer’s Disease, Agitation, Schizophrenia, Narcolepsy, Sleep Disorders, Major Depressive Disorder, and Parkinson’s Disease. The posters highlight Suven’s continued progress in advancing innovative drug candidates through clinical and preclinical development.
Key Presentations
Suven will present the following seven posters: SUVN-M8036: A Multimodal Receptor Antagonist That Exhibits Antipsychotic and Anti-Aggressive-Like Effects in Animal Models; SUVN-I6107 (Tenaclidine): Safety, Tolerability, and Pharmacokinetics of a Pure M1 Positive Allosteric Modulator: Results from a First-in-Human Study in Healthy Subjects; SUVN-L1101142: A Novel Muscarinic M4 Positive Allosteric Modulator for the Treatment of Alzheimer’s Disease and Schizophrenia; Samelisant: Efficacy and Safety of an H3 Receptor Inverse Agonist for the Treatment of Narcolepsy With or Without Cataplexy: A Phase 3 Study; SUVN-N9503012: Efficacy of a Selective 5-HT1A Receptor Partial Agonist Intended for the Treatment of L-Dopa-Induced Dyskinesia; Ropanicant (SUVN-911): A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety in Patients with Major Depressive Disorder; Masupirdine (SUVN-502): Baseline Characteristics from a Phase-3 Study in Alzheimer’s Dementia with Agitation.
Suven’s participation at Neuroscience 2026 reflects the breadth and continued progress of its CNS research and development pipeline. The company remains committed to advancing innovative therapies that address significant unmet medical needs, improve outcomes for patients, and create long-term value for the company.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Suven Life Sciences Limited
Suven Life Sciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Suven falls 14.9% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock holds at 55% of its 52-week range with RSI at 37. In other words, neither side has a clear edge right now. The stock holds up despite -19.3% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Suven Life Sciences Limited.
Healthcare
Lupin Limited Announces European Launch of Biosimilar Ranibizumab
Lupin Limited (LUPIN) announces the European launch of its biosimilar Ranibizumab, expanding access to retinal disease treatment.
Lupin Limited (LUPIN) today announced that its commercial partner, Sandoz, has launched RanluspecTM, Lupin’s biosimilar Ranibizumab, across Europe, excluding Germany. This launch follows the European Commission approval of RanluspecTM in vial and pre-filled syringe presentations and marks an important step in expanding access to high-quality biologic treatment options for retinal diseases.
Strategic Milestone
Thierry Volle, President EMEA and Emerging Markets, Lupin, said, “The launch of Ranluspec in Europe advances Lupin’s strategy of bringing high-quality biosimilars to more patients suffering from retinal and choroidal vascular diseases. Together with Sandoz, we will expand access to this important treatment across the region.”
Commitment to Healthcare
“The launch of Ranluspec reinforces our growing capabilities in biosimilars as it brings together our scientific expertise and manufacturing capabilities in biologics. It underscores our commitment to addressing unmet needs while supporting more sustainable healthcare systems,” said Dr. Cyrus Karkaria, President – Biotech Business, Lupin.
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. The company specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. With 15 state-of-the-art manufacturing sites and 6 research centers globally, Lupin is committed to improving patient health outcomes.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Lupin Limited
Lupin Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Lupin drops 22.9% over three months and trades near its 52-week lows. The PEG of 0.12 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. The business compounds revenue at 19.1% and profits at 131.5% CAGR. That is strong double-digit growth on both counts. The stock sits at 6% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 19.1% and profits at 131.5% CAGR, with D/E of 0.32. Meanwhile, the stock dips 22.9% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Lupin Limited.
-
HIRECT3 days agoHirect Limited Q2 & H1 FY27: Highest-ever Revenue, Strong Business Momentum
-
Consumer Cyclical3 days agoKalyan Jewellers India Limited (kalyankjil) Q2 FY27: Revenue Surpasses Rs 10,300 Crore, PAT Rises 64%
-
Basic Materials3 days agoVishnu Chemicals Limited Q2fy27: Strategic JV with DCX Chrome SAS, Ebitda Grows 10% Yoy
-
Credit Services3 days agoIifl Finance Limited to Raise ₹6,414 Crores ($686 Million) in Major Private Equity Infusion
-
Basic Materials3 days agoJindal Stainless Limited (JSL) Wins 95 Gold and 6 Silver Awards at QCFI Conventions 2026
-
Communication Services3 days agoMatrimony.com Limited Q2 FY26: PAT Growth of 167% Y/y
-
ADANIENT2 days agoAdani Enterprises Limited (adanient) Kutch Copper First Indian Producer to Receive Veramark Assurance Certification
-
Consumer Defensive2 days agoCupid Limited (NSE: Cupid) Q2 FY27: Net Profit Growth of 133% Yoy; H1 FY27 Net Profit Rises 156% Yoy to ₹100.37 Crore